Want to see GB:CRDA full AI Analyst Report?
CRDA Stock Chart & Stats
3051.00 p
11.00 p(0.34%)
At close: 4:00 PM EST
3051.00 p
11.00 p(0.34%)
Day’s Range― - ―
52-Week Range2,426.77 p - 3,312.00 p
Previous CloseN/A
Volume8.09K
Average Volume (3M)650.08K
Market Cap
£4.19B
Enterprise Value4.85B
Total Cash (Recent Filing)£172.80M
Total Debt (Recent Filing)£696.60M
Price to Earnings (P/E)67.4
Beta1.31
Next Earnings
Jul 28, 2026EPS Estimate
0.78Next Dividend Ex-DateN/A
Dividend Yield3.45%
Share Statistics
EPS (TTM)0.45
Shares Outstanding139,635,440
10 Day Avg. Volume610,745
30 Day Avg. Volume650,080
Financial Highlights & Ratios
PEG Ratio-1.00
Price to Book (P/B)1.72
Price to Sales (P/S)2.21
P/FCF Ratio21.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£3,493.00Price Target Upside14.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.57
Revenue Forecast (FY)£1.77B
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent operating cash flow and a marked FCF improvement in 2025 provide durable internal funding for transformation, capex and dividends. Strong cash generation supports deleveraging, funds targeted savings and gives flexibility to absorb cyclical downturns without undermining core operations.
Balance-sheet StrengthRelatively low leverage and sizable equity create financial resilience through the restructuring period. A conservative capital structure lowers refinancing risk, supports the target net-debt/EBITDA range and preserves capacity to fund strategic investments or accelerate transformation without jeopardising solvency.
Portfolio Shift To High-growth NichesA deliberate repositioning toward consumer, pharma and agriculture plus growth in patented ingredients increases exposure to higher-value, formulation-led demand. Geographic diversification (48% outside Europe/N.A.) and stronger NPS imply stickier customer relationships and sustained premium pricing potential over the medium term.
Bears Say
Large Impairment And Exceptional ChargesMaterial one-off impairments and exceptional charges signal prior overcapacity or misallocated investments and reduce reported equity and earnings quality. They can presage further write‑downs and increase near-term headline volatility, complicating investor assessment of core operating performance.
Segment Volatility And Customer ConcentrationMarked swings in Pharma Solutions and Industrial Specialties, and reliance on large customer relationships (e.g., Cargill exposure in IS), create structural unpredictability in volumes and margins. Policy shifts, product timing and single-customer effects may limit reliable top-line and margin progression.
Revenue And Profit NormalizationEarnings normalized materially after an exceptional 2022 peak, with revenue swings and lower net income reducing compounding of returns. Sustained improvement depends on delivery of transformation savings and durable mix shifts; until then ROIC and return metrics may remain constrained.
Croda International News
CRDA FAQ
What was Croda International PLC’s price range in the past 12 months?
Croda International PLC lowest share price was 2426.77 p and its highest was 3312.00 p in the past 12 months.
What is Croda International PLC’s market cap?
Croda International PLC’s market cap is £4.19B.
When is Croda International PLC’s upcoming earnings report date?
Croda International PLC’s upcoming earnings report date is Jul 28, 2026 which is in 26 days.
How were Croda International PLC’s earnings last quarter?
Croda International PLC released its earnings results on Feb 24, 2026. The company reported 0.74 p earnings per share for the quarter, beating the consensus estimate of 0.684 p by 0.056 p.
Is Croda International PLC overvalued?
According to Wall Street analysts Croda International PLC’s price is currently Undervalued.
Does Croda International PLC pay dividends?
Croda International PLC pays a Semiannually dividend of 63 p which represents an annual dividend yield of 3.45%. See more information on Croda International PLC dividends here
What is Croda International PLC’s EPS estimate?
Croda International PLC’s EPS estimate is 0.78.
How many shares outstanding does Croda International PLC have?
Croda International PLC has 139,635,440 shares outstanding.
What happened to Croda International PLC’s price movement after its last earnings report?
Croda International PLC reported an EPS of 0.74 p in its last earnings report, beating expectations of 0.684 p. Following the earnings report the stock price went up 7.605%.
Which hedge fund is a major shareholder of Croda International PLC?
Currently, no hedge funds are holding shares in GB:CRDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Croda International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£3,493.00 (14.49% Upside)
£3,493.00 (14.49% Upside)
Blogger Sentiment
Bullish
GB:CRDA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth £4.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.88%
12-Months-Change
Fundamentals
Return on Equity
2.82%
Trailing 12-Months
Asset Growth
-2.80%
Trailing 12-Months
Company Description
Croda International PLC
Croda International Plc, established in 1925 and headquartered in Goole, United Kingdom, is a global leader in the development, manufacture, and supply of high-performance specialty chemicals. The company serves a diverse international client base across Europe, the Middle East, Africa, North America, Asia, and Latin America. Its operations are organized into four primary business segments: Consumer Care, Life Sciences, Performance Technologies, and Industrial Chemicals. Croda's extensive product portfolio addresses a wide array of industrial and consumer needs. For the Consumer Care market, it delivers crucial ingredients for personal care products, spanning skin, hair, sun, and baby care, along with solutions for color cosmetics, oral hygiene, self-tanning, deodorants, men's grooming, and depilatories, as well as household and institutional cleaning formulations. In Life Sciences, the company provides innovative solutions for agriculture, including crop protection additives, seed enhancements, animal health chemicals, and bio-stimulants, alongside dietary supplements and active pharmaceutical ingredients. The Performance Technologies and Industrial Chemicals segments encompass a vast range of specialized materials. This includes additives for lubricants, coatings, polymers, batteries, and catalysts; materials for electronics, construction, and thermal management; adhesives; and chemicals for vehicle cleaning, automotive textiles, and plastic/rubber products. Furthermore, Croda supplies chemicals for packaging, printing, paper, paints, and water treatment, along with oleochemicals, emulsifiers, fuel additives, and specialty polymer additives for furniture and wood. The company also innovates in bio-based phase change materials, offering solutions for temperature control in buildings, clothing, healthcare, electronics, food refrigeration, energy storage, packaging, and automotive applications. This broad offering underscores Croda's commitment to delivering specialized chemical solutions across numerous critical industries.
CRDA Stock 12 Month Forecast
Average Price Target
3,493.00 p
▲(14.49% Upside)
Technical Analysis
Options Prices
Currently, No data available
---






